Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.

P. Kinsella,R. Howley,P. Doolan,C. Clarke,S. Madden,M. Clynes,M. Farrell,V. Amberger-Murphy
DOI: https://doi.org/10.1016/j.yexcr.2012.01.014
IF: 4.145
2012-03-10
Experimental Cell Research
Abstract:
What problem does this paper attempt to address?